BioSpace News Archive

RIVANNA®, developers of imaging-based medical solutions, announced that they have received funding totaling $30.5 million over 39 months from early execution of an option by the Biomedical Advanced Research

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, reported certain preliminary financial results for the first half of 2023, including its cash, cash equivalents, and revenues, and provided a corporate update.

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) will report financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the market, and provide a corporate update.

Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that William “Trey” Martin, III has assumed the role of Chief Executive Officer (CEO) of Maravai LifeSciences effective July 27, 2023, consistent with the Company’s previously announced CEO succession plan.

Invivyd, Inc., a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced the appointment of Sara Cotter to its board of directors.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced the appointment of Pius Maliakal, M. Pharm., Ph.D., as Vice President of Clinical Operations.

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has completed a review of its business, and the Board of Directors has approved a plan to evaluate strategic alternatives to maximize shareholder value.

Seer, Inc., a leading life sciences company commercializing a disruptive new platform for proteomics, announced that the company will be participating in the upcoming Canaccord Genuity 43rd Annual Growth Conference in Boston, MA.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced its half year 2023 financial results and provided a second quarter business update.

Galderma maintained strong momentum across all product categories reaching 2,003 M USD net sales in H1 2023, up 6.9% year-on-year on a constant currency basis.